BVS insider trading
NasdaqGS HealthcareBioventus Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Company website: www.bioventus.com
BVS insider activity at a glance
FilingIQ has scored 236 insider transactions for BVS since Feb 11, 2021. The most recent filing in our index is dated Apr 10, 2026.
Across the full history, 26 open-market purchases
and 50 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BVS insider trades is 59.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BVS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding BVS
Frequently asked
- How many insider trades does FilingIQ track for BVS?
- FilingIQ tracks 236 Form 4 insider transactions for BVS (Bioventus Inc.), covering filings from Feb 11, 2021 onwards. 48 of those were filed in the last 90 days.
- Are BVS insiders net buyers or net sellers?
- Across the full Form 4 history for BVS, 26 transactions (11%) were open-market purchases and 50 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BVS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is BVS in?
- Bioventus Inc. (BVS) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $568.63M.
Methodology & sources
Every BVS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.